Human immunodeficiency virus infection in pregnancy

Area of Science:

• Obstetrics and Gynecology
• Infectious Diseases
• Immunology

Background:

• Many aspects of human immunodeficiency virus (HIV) infection in pregnancy are not well understood.
• Identifying specific patient subsets at increased risk for perinatal transmission, adverse pregnancy outcomes, and symptomatic HIV infection is essential.
• Current understanding of risk stratification based on T4 lymphocyte counts and symptomatic status in pregnant individuals with HIV is limited.

Purpose of the Study:

• To highlight the need for identifying subsets of pregnant individuals with HIV at increased risk.
• To discuss the potential impact of future antiviral therapies on perinatal HIV transmission.
• To emphasize the evolving role of obstetricians in managing HIV-infected pregnant patients.

Main Methods:

• This abstract does not detail specific experimental methods.
• It relies on existing knowledge and clinical observations regarding HIV in pregnancy.
• It discusses potential future therapeutic strategies and their implications.

Main Results:

• Relative risks for perinatal transmission and adverse outcomes may differ significantly based on HIV symptomology and T4 lymphocyte counts (e.g., >200 cells/mm³ vs. <200 cells/mm³).
• Currently, pregnant women and neonates are excluded from antiviral therapeutic trials.
• Antiviral therapy, such as AZT, holds potential for reducing transplacental and intrapartum HIV transmission in the future.

Conclusions:

• Further research is needed to identify specific risk factors for adverse outcomes in pregnant individuals with HIV.
• Antiviral therapies, including AZT, are expected to play a significant role in preventing perinatal HIV transmission.
• Obstetricians will require increased involvement in patient care and HIV prevention education.